Bibliography
- Folkman J : Tumor angiogenesis: therapeutic implications.N. Engl. J. Med.285, 1182–1186 (1971).
- Folkman J , MerlerE, AbernathyC, WilliamsG: Isolation of a tumor factor responsible for angiogenesis.J. Exp. Med.133, 275–288 (1971).
- Ribatti D : The discovery of antiangiogenic molecules: a historical review.Curr. Pharm. Des.15, 345–352 (2009).
- Boehm-Viswanathan T : Is angiogenesis inhibition the Holy Grail of cancer therapy?Curr. Opin. Oncol.12, 89–94 (2000).
- Hurwitz H , FehrenbacherL, NovotnyWet al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N. Engl. J. Med.350, 2335–2342 (2004).
- Saltz LB , ClarkeS, Diaz-RubioEet al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study.J. Clin. Oncol.26, 2013–2019 (2008).
- Windsor AC , CohenR, JiaoLR, StebbingJ: Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear.Future Oncol.4, 741–744 (2008).
- Meyerhardt JA , MayerRJ: Systemic therapy for colorectal cancer.N. Engl. J. Med.352, 476–487 (2005).
- Adam R , DelvartV, PascalGet al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.Ann. Surg.240, 644–657; discussion 657–648 (2004).
- Adam R , WichertsDA, de HaasRJet al.: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?J. Clin. Oncol.26, 1635–1641 (2008).
- Kim TI , ChungJL, HongJP, MinK, SeoKY, KimEK: Bevacizumab application delays epithelial healing in rabbit cornea.Invest. Ophthalmol. Vis. Sci. (2009) (Epub ahead of print).
- Gordon CR , RojavinY, PatelMet al.: A review on bevacizumab and surgical wound healing: an important warning to all surgeons.Ann. Plast. Surg.62, 707–709 (2009).
- Kesmodel SB , EllisLM, LinEet al.: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.J. Clin. Oncol.26, 5254–5260 (2008).
- Scappaticci FA , FehrenbacherL, CartwrightTet al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.J. Surg. Oncol.91, 173–180 (2005).
- D’Angelica M , KornpratP, GonenMet al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.Ann. Surg. Oncol.14, 759–765 (2007).
- Reddy SK , MorseMA, HurwitzHIet al.: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.J. Am. Coll. Surg.206, 96–106 (2008).
- Nalluri SR , ChuD, KeresztesR, ZhuX, WuS: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.JAMA300, 2277–2285 (2008).
- Scappaticci FA , SkillingsJR, HoldenSNet al.: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.J. Natl. Cancer Inst.99, 1232–1239 (2007).
- August DA , SerranoD, PoplinE: “Spontaneous”, delayed colon and rectal anastomotic complications associated with bevacizumab therapy.J. Surg. Oncol.97(2), 180–185 (2008).